Connect with us

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) Signs Licensing and Royalty Agreement For Commercialization of Avicanna’s Topical Products

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS: HERTF) has entered an exclusive intellectual property license and royalty agreement with Avicanna Inc. Avicanna is a biopharma company specializing in developing, manufacturing, and marketing plant-based CBD products.

Heritage Cannabis signs licensing agreement with Avicanna

The Agreement is for marketing a range of Avicanna’s advanced CBD-based topical solutions under Heritage medical cannabis brands, aimed towards patients who have registered to acquire medicinal cannabis in Canada.

Avicanna’s patented CBD topical formulations, created over years of rigorous research by the company’s team of scientists, are among the Branded Products to be marketed. The products are all backed up by pre-clinical research, except for two SKUs backed up by completed human trials. Heritage’s broad medical sales channels in Canada will launch the Branded Products in Q4 2021, with the goal of meeting unmet medical requirements in the vast market with scientifically researched and standardized CBD products.

Heritage’s medical division president Umar Syed said, “We are excited to add Avicanna’s innovative topical products to our portfolio of highly effective medical CBD products. They are a great strategic fit. We are very impressed with Avicanna’s diligent R&D approach for developing highly effective topical products formulated with pharmaceutical technology and which are supported with evidence of efficacy, much like the existing Opticann portfolio that includes oral products that use the patented VESIsorb technology and sublingual CBD filmstrips that use the patented Versafilm® technology. The Licensing Agreement offers Heritage speed-to-market with highly effective topicals.”

Avicanna is glad to extend its products to more Canadians

Aras Azadian, Avicanna CEO, commented, “We look forward to collaborating with the Heritage team to extend our proprietary and evidence-based topical formulations to more Canadian patients and expand into more medical channels nationwide. We believe that the alignment of both companies to offer the highest standards for cannabinoid-based medicine and education will yield fruitful and long-term commercial success.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Lexaria Bioscience Corp (NASDAQ: LEXX) Expected to Offer Safe, Effective, and Affordable Treatment

Published

on

Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces that the company’s name features in an editorial published by NetworkNewsWire, a trusted brand within the InvestorBrandNetwork. In addition, the company states that they lead the way of innovation in Hypertension Treatment, which is safe and effective.

The company to lead industry in providing affordable treatment

One of the most pervasive diseases in first-world countries is heart disease, one of the leading causes of death for women and men in the United States. As per the industry, one person dies every 36 seconds from cardiovascular disease. According to the CDC (Centers for Disease Control and Prevention), either high blood pressure or hypertension is one of the critical risk factors for heart disease and stroke. The industry also stated that almost 50% of adults in the United States have hypertension. Of which, only ~24% of the hypertension patients have their condition under control. 

The industry needs to find effective treatments for the most pervasive diseases, with many companies leading innovation. Lexaria Bioscience Corp is one company working on innovative medicine, with its patented drug delivery DehydraTECH(TM). The company is joining a group of companies working together to provide safe, effective, and affordable treatment.

Results showing positive development

As per the company, a human clinical study using DehydraTECH technology showed a fast and sustained fall in blood pressure. It is a step forward by the company to treat hypertension, particularly in stage 2 hypertensive volunteers. Initial trial results show that blood pressure declined amongst the adults and was seen within the 10-50 minutes of the study. The results reinforce, DehydraTECH delivers far superior performance over the generic controls. Industry experts also indicated that the results are promising for patients at risk of hypertension and provide fundamental support for expanding clinical trials.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Reliq Health Technologies Inc (OTCMKTS: RQHTF) Signed a New Contract to Provide iUGO Platform

Published

on

Reliq Health Technologies Inc (OTCMKTS: RQHTF) is the fastest growing global telemedicine company, developing innovative Virtual Care solutions for the Healthcare market. In addition, the company announced that they had signed a new contract with six new U.S primary care physician practices for providing its iUGO care platform for their chronic disease patients.

Contract with six new U.S. primary care physician practices

The company entered into a contract with six new U.S primary care physician practices. Moreover, the company added 4,000 new patients to its iUGO care platform. As per the agreement, all the primary care physician practices will be using Reliq Health Technologies iUGO Care RPM (Remote Patient Monitoring), CCM (Chronic Care Management and BHI (Behavioural Health Integration) modules. Reliq’s iUGO Care platform supports care coordination and community-based virtual healthcare monitoring. In addition, the platform also provides real-time access to remote patient monitoring data, timely interventions by the care team to prevent costly hospital readmissions.

The company is likely to report the first full profitable quarter

As per the company, the average revenue from the new contract is likely to be >$40 per patient per month. The company further stated that the onboarding of all the six new physicians is likely to start in the current month and be completed by October. Moreover, the recent client acquisition and patient enrolling are gaining space rapidly since July and are expected to continue strong growth in the coming months. As per the industry, the new physician and enrolling of new patients are expected to support the company revenue starting from October. The significant benefit of the same will come in FY22. The September quarter will be the company’s first full profitable quarter, which is a significant development.

New physicians and over 4,000 new patients give the company strong revenue visibility starting from the current month and significant benefits from November. The higher volume is also expected to support the operating leverage, thereby strengthening the company’s operating performance. However, the industry believes this is just the beginning for the company, and profitability growth is likely to see a sharp increase as the onboarding of the patients increases.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

CordovaCann Corp (OTCMKTS: LVRLF) Sold Assets Worth $2.2 Billion and Entered into a Lease Agreement

Published

on

CordovaCann Corp (OTCMKTS: LVRLF) is a cannabis-focused consumer product company, announced that the company has sold all of its equipment, land, and building for $2.2 billion and simultaneously entered into an agreement with the buyer to lease the property for ten years, with an option of renewal for a two subsequent ten years period.

Sold assets and signed a lease agreement

In its press release, the company stated that its wholly-owned subsidiary Cordova OR Operations, LLC, has sold its equipment, land, and building for $2.2 million and entered into an agreement to lease the property from the buyer. The lease will allow the company to operate on the property for ten (10) years. In addition, it also provides an option for two subsequent renewals of the lease for ten (10) year periods. 

The management stated that the proceeds from the sale of the assets would be utilized to repay debts related to the property and fund the planned expansion at Cannabilt. In addition, around $0.6 million of the transaction amount has been placed in an escrow account to allow the company to complete its facility buildout. The company further stated, the lease commenced on August 1, 2021. As per the agreement, the Cannabilt will not pay any rent during the first three months. Post completion of the three months, the company will pay $22,000 every month for the remaining part of the year, with an escalation clause after that.

Expansion to introduce a new derivative product

As per the company, the sale and leaseback agreement enables the company to moves forward with its Cannabilt Farms initiatives in Oregon. The company has already started executing its expansion plan with an expectation of introducing a new flower strain and line of cannabis derivative products by the end of the year. Moreover, as per the company, the amount deposited in an escrow account $0.6 million, is enough for the company to fund its expansion plan in the coming months. In addition, the current transaction will also enable the company to extinguish all its debts obligation and strengthen its balance sheet. The transaction is also likely to increase the profitability of the company in the coming months.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories